Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

Rhea-AI Summary

Anavex Life Sciences (NASDAQ: AVXL), a clinical-stage biopharmaceutical company developing treatments for neurological conditions, announced its participation in two upcoming healthcare conferences. CEO Christopher U. Missling will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th, 2025, at 2:30 pm ET, and the H.C. Wainwright 6th Annual Neuro Perspectives Conference on June 17th, 2025, at 7:00 pm ET. Both events will be held in New York City, with webcasts available to firm clients at hcwevents.com.

The company focuses on innovative treatments for various conditions including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other CNS disorders.

H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives Conference

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that its President & Chief Executive Officer, Christopher U. Missling, PhD, will participate at both the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6^th Annual Neuro Perspectives Conference. Both conferences will take place in New York City (NY).

• H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
  When: Tuesday, May 20^th, 2025 at 2:30 pm ET.
  A webcast is available to clients of the firm at https://hcwevents.com/.

• H.C. Wainwright 6^th Annual Neuro Perspectives Conference
  When: Tuesday, June 17^th, 2025 at 7:00 pm ET.
  A webcast is available to clients of the firm at https://hcwevents.com/.

About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX^®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX^®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX^®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX^®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX^®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX^®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.

Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com

Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com

FAQ

When is Anavex Life Sciences (AVXL) presenting at the H.C. Wainwright BioConnect Conference 2025?

Anavex Life Sciences (AVXL) will present at the H.C. Wainwright BioConnect Conference on Tuesday, May 20th, 2025 at 2:30 pm ET in New York City.

When is AVXL presenting at the H.C. Wainwright Neuro Perspectives Conference 2025?

Anavex Life Sciences will present at the H.C. Wainwright Neuro Perspectives Conference on Tuesday, June 17th, 2025 at 7:00 pm ET in New York City.

What diseases is Anavex Life Sciences (AVXL) developing treatments for?

Anavex is developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other neurodevelopmental, neurodegenerative, and rare diseases affecting the central nervous system (CNS).

Who is presenting at the H.C. Wainwright conferences for Anavex Life Sciences?

Christopher U. Missling, PhD, President & Chief Executive Officer of Anavex Life Sciences, will be presenting at both conferences.